Clinical trials: Breast Neoplasms, Triple-Negative
Triple -Negative Breast Cancer, Estrogen Receptor Negative
Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer
This pilot trial studies how well chemokine modulation therapy works when given prior to pembrolizumab in treating participants with triple-negative breast cancer that has spread to other places in the body.
- Conditions
- Triple -Negative Breast Cancer, Estrogen Receptor Negative, HER2/Neu Negative, Anatomic Stage IV Breast Cancer AJCC
- Trial name
- NCT03599453
- Testing
- Biopsy, Chemokine Modulation Therapy, Celecoxib
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Roswell Park Cancer Institute
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer
This clinical trial aims to see if patients with triple negative breast cancer can complete a biobehavioral stress reduction program that also addresses health related social needs (e.g., utilities, transportation, etc.).
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma
- Trial name
- NCT05677802
- Testing
- Biospecimen Collection, Medical Chart Review, Stress Management Therapy
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer
Study of XB010 in Subjects With Solid Tumors
This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- NCT06545331
- Testing
- XB010, Pembrolizumab
- Where
- 20 sites in United States, United Kingdom
- Volunteers
- 396 people
- Sponsor
- Exelixis
Metastatic Breast Cancer, Locally Advanced Breast Cancer
A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer
This study is to evaluate safety and efficacy of an antibody drug conjugate U3-1402 (patritumab deruxtecan) in patients with locally advanced or metastatic breast cancer (MBC).
- Trial name
- NCT04699630
- Testing
- U3-1402
- Where
- 11 sites in United States
- Volunteers
- 121 people
- Sponsor
- SCRI Development Innovations, LLC
Solid Tumor, Non-small Cell Lung Cancer
A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
This study is evaluating the safety, side effects, how the body processes HH160, and its early anticancer activity when given alone or with other cancer treatments in participants with advanced solid tumors.
- Conditions
- Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT07623369
- Testing
- HH160
- Where
- 3 sites in Australia, China
- Volunteers
- 299 people
- Sponsor
- Huahui Health
Triple-negative Breast Cancer
Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer
This is a Phase II, open-label, single-arm study evaluating the efficacy and safety of combined treatment of Inosine with chemotherapy in mTNBC (triple negative breast cancer) patients who progressed during previous chemotherapy.
- Trial name
- NCT06355024
- Testing
- Inosine, Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Fudan University
TNBC - Triple-Negative Breast Cancer
Immunotherapy-related CRP Kinetics in Early and Metastatic Triple-negative Breast Cancer
ICK-breast is a prospective, multicentric, non-interventional investigator-initiated trial (IIT) that aims to investigate the prognostic value of CRP kinetics in early and advanced or metastatic triple negative breast cancer…
- Trial name
- NCT05914961
- Where
- Germany
- Volunteers
- 225 people
- Sponsor
- University Hospital Tuebingen
Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma
A Study of LY4175408 in Participants With Advanced Cancer
The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis
- Trial name
- NCT07046923
- Testing
- LY4175408, Pembrolizumab, Carboplatin
- Where
- 27 sites in United States, China and 4 more
- Volunteers
- 240 people
- Sponsor
- Eli Lilly and Company
Triple Negative Breast Neoplasms
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)
The purpose of this study is to evaluate the efficacy and safety of pembrolizumab (MK-3475) plus chemotherapy vs placebo plus chemotherapy as neoadjuvant therapy and pembrolizumab vs placebo as adjuvant therapy in participants…
- Trial name
- NCT03036488
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- 193 sites in United States, Australia and 19 more
- Volunteers
- 1,174 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Neoplasms
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
This is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatment group.
- Trial name
- NCT07173751
- Testing
- Pumitamig, Nab-paclitaxel/Paclitaxel, Gemcitabine
- Where
- 224 sites in United States, Argentina and 17 more
- Volunteers
- 558 people
- Sponsor
- BioNTech SE
Breast Cancer
Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.
The purpose of this study is to determine how well this combination of chemotherapy drugs works with bevacizumab in eliminating primary tumor in the breast prior to surgery(pathological complete response or pCR in the breast).
- Trial name
- NCT00777673
- Testing
- Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Tennessee Cancer Institute
Breast Cancer
Eliminating Breast Surgery for Breast Cancer Patients With Clinical Complete Response to Neoadjuvant Systemic Therapy
Phase II multicenter prospective study on the safety of eliminating surgery for triple negative or HER2 positive breast cancer patients with clinical response to neoadjuvant radiotherapy and neoadjuvant chemotherapy.
- Trial name
- NCT06498154
- Testing
- Neoadjuvant Chemotherapy combined with Neoadjuvant Radiotherapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non-Small Cell Lung Cancer, Triple-negative Breast Cancer
Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC
Part 1of the study will evaluate the safety, pharmacokinetics, pharmacodynamics and immunogenicity of increasing doses of a vaccine-based immunotherapy regimen (VBIR-2) for patients with advanced or metastatic non-small cell lung…
- Trial name
- NCT03674827
- Testing
- PF-06936308
- Where
- 34 sites in United States
- Volunteers
- 36 people
- Sponsor
- Pfizer
Metastatic Colorectal Cancer, Triple Negative Breast Cancer
Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors
To determine the efficacy (as measured by overall tumour response rate) of the combination of durvalumab and tremelimumab when given to previously treated patients with solid tumors harboring a high mutational load.
- Conditions
- Metastatic Colorectal Cancer, Triple Negative Breast Cancer, Prostate Adenocarcinoma, Stomach Adenocarcinoma
- Trial name
- MATILDA (NCT03982173)
- Testing
- Tremelimumab, Durvalumab
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
This randomized phase II trial studies how well paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide works in treating patients with breast cancer that can be removed by surgery.
- Conditions
- Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7
- Trial name
- NCT00861705
- Testing
- Bevacizumab, Carboplatin, Cyclophosphamide
- Where
- 448 sites in United States
- Volunteers
- 454 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer
The purpose of this study is to determine the impact of pre-operative cryoablation, and immune checkpoint inhibition (ICI) on on 3-year Event Free Survival (EFS), in women with residual hormone receptor negative, HER2-negative…
- Trial name
- NCT03546686
- Testing
- Pembrolizumab, Core Biopsy/Cryoablation, Breast Surgery
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- University of Texas Southwestern Medical Center
Advanced Solid Tumor
PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors
This study aims to evaluate the efficacy of CVL218 in combination with Toripalimab injection/Sintilimab injection (Darbersol, Sintilimab) in the treatment of advanced solid tumors.
- Trial name
- NCT06078670
- Testing
- CVL218
- Volunteers
- 96 people
- Sponsor
- Fujian Cancer Hospital
Advanced Triple Negative Breast Cancer
Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer
This study is a single-arm,exploratory clinical study, to evaluate the effectiveness and safety of apatinib mesylate combined with albumin-bound paclitaxel for second-line treatment of advanced triple negative breast cancer.
- Trial name
- NCT05019690
- Testing
- Apatinib Mesylate, Albumin-Bound Paclitaxel
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Fujian Cancer Hospital
Triple Negative Breast Cancer
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
The goal of this clinical study is to learn more about the study drug sacituzumab govitecan-hziy (SG) given at an alternative dose and schedule, in participants with triple-negative breast cancer (TNBC).
- Trial name
- NCT06926920
- Testing
- Sacituzumab Govitecan-hziy (SG)
- Where
- 16 sites in United States, Australia and 1 more
- Volunteers
- 100 people
- Sponsor
- Gilead Sciences
Breast Cancer
Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer
The purpose of this study is to assess the efficacy and safety of Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast patients
- Trial name
- NCT03735082
- Testing
- Apatinib, Paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Chinese Academy of Medical Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.